CNS Pharmaceuticals, Inc. has achieved a key milestone for the U.S. manufacture of Berubicin, the company’s lead drug candidate for the treatment of malignant gliomas, in preparation for upcoming clinical trials. CNS previously implemented a dual-track drug product manufacturing strategy and contracted U.S.-based Pharmaceutics International, Inc. (Pii) and Italy-based BSP Pharmaceuticals for the production of Berubicin. By engaging two separate manufacturers on two separate continents,...